Drug Farm's DF-003 Receives FDA Fast Track Designation for ROSAH Syndrome Treatment
核心洞察
Drug Farm (搜索) announced that the FDA has granted Fast Track designation to DF-003, a first-in-class ALPK1 (搜索) inhibitor for treating ROSAH syndrome (搜索), a rare autoinflammatory disease with no approved therapies.
DF-003 is a structurally novel, orally administered small-molecule inhibitor that crosses blood-retina and blood-brain barriers and significantly suppresses inflammatory cytokines in preclinical models.
The drug has completed Phase 1 trials in healthy volunteers and is currently enrolling patients in a Phase 1b clinical trial, with results expected to be reported in 2026.
Drug Farm (搜索), a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration has granted Fast Track designation to DF-003, its investigational first-in-class ALPK1 (搜索) inhibitor, for the treatment of ROSAH syndrome (搜索). The rare, autosomal dominant autoinflammatory disease currently has no approved therapies available to patients.
Fast Track designation is designed to facilitate development and expedite review of drugs intended to treat serious or life-threatening conditions that address unmet medical needs. The designation enables more frequent interactions with the FDA and allows eligibility for rolling review and, if relevant criteria are met, priority review.
Novel Mechanism Targets Disease Root Cause
DF-003 represents a structurally novel, orally administered small-molecule inhibitor that potently and selectively inhibits disease-causing mutant ALPK1 (搜索), including the ROSAH-associated ALPK1 T237M variant. Preclinical studies demonstrated that DF-003 crosses the blood-retina and blood-brain barriers and significantly suppresses inflammatory cytokines and disease-associated phenotypes in a mouse model of ROSAH syndrome (搜索).
"We have designed DF-003 to directly target the genetic root cause of ROSAH syndrome (搜索)," said Henri Lichenstein, Ph.D., Chief Executive Officer of Drug Farm (搜索). "The FDA's Fast Track designation recognizes the serious nature of this disease and the urgent need for targeted, disease-modifying therapies, and it supports our efforts to accelerate development of DF-003 for patients."
Clinical Development Progress
DF-003 is the first ALPK1 (搜索) inhibitor to successfully complete a first-in-human Phase 1 study and has now entered a Phase 1b clinical trial in patients with ROSAH syndrome (搜索) (NCT06395285), where it is being evaluated for safety, pharmacokinetics, pharmacodynamics and efficacy. Clinical data from the trial will be reported at meetings in 2026.
The drug has completed a Phase 1 clinical trial (NCT05997641) in normal healthy volunteers and is now accruing patients with ROSAH syndrome (搜索) in the Phase 1b trial. Beyond ROSAH syndrome, DF-003 has shown therapeutic potential for heart and kidney diseases, demonstrating efficacy in preclinical models of these indications.
Addressing Critical Unmet Need
ROSAH (retinal dystrophy (搜索), optic nerve edema (搜索), splenomegaly (搜索), anhidrosis (搜索), and headache) syndrome is a rare, autosomal dominant autoinflammatory genetic disease caused by activating mutations in the ALPK1 (搜索) gene. The disease is characterized by progressive visual loss, optic nerve and retinal pathology, and systemic inflammatory manifestations, including elevated pro-inflammatory cytokines. Symptoms often begin in childhood or early adulthood.
"I am encouraged by the progress of DF-003 and the FDA's decision to grant Fast Track designation," said Dr. John Grigg, Professor of Clinical and Experimental Ophthalmology, Save Sight Institute Faculty of Medicine and Health at The University of Sydney. "Patients with ROSAH syndrome (搜索) currently have no approved treatment options, and therapies that can modify disease progression have the potential to meaningfully preserve vision and improve quality of life."
Company Platform and Pipeline
Drug Farm (搜索) is a private biotechnology company developing innovative treatments targeting innate immunity for hepatitis B (搜索), heart and kidney diseases, and ROSAH syndrome (搜索). The company's unique IDInVivo platform combines breakthrough technologies in genetics and artificial intelligence to identify and validate novel drug targets directly in living animals with intact immune systems. Using this platform, Drug Farm is advancing multiple first-in-class drug candidates into clinical development.